Published in Virology on January 05, 2003
Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. J Virol (2005) 7.36
Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis (2005) 6.99
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol (2006) 2.47
Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol (2007) 2.39
An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A (2005) 2.33
Influenza: emergence and control. J Virol (2004) 2.31
The PA subunit is required for efficient nuclear accumulation of the PB1 subunit of the influenza A virus RNA polymerase complex. J Virol (2004) 2.30
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A (2005) 2.13
Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One (2009) 1.95
Influenza A virus neuraminidase limits viral superinfection. J Virol (2008) 1.79
Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev (2006) 1.52
Influenza vaccines based on virus-like particles. Virus Res (2009) 1.48
Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology (2010) 1.39
Restrictions to the adaptation of influenza a virus h5 hemagglutinin to the human host. J Virol (2004) 1.37
Vaccines for pandemic influenza. Emerg Infect Dis (2006) 1.37
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine (2007) 1.35
Complex reassortment of multiple subtypes of avian influenza viruses in domestic ducks at the Dongting Lake Region of China. J Virol (2013) 1.30
H5N1 viruses and vaccines. PLoS Pathog (2007) 1.30
Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res (2008) 1.30
Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol (2004) 1.28
Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol (2007) 1.27
Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza viruses. J Clin Microbiol (2011) 1.21
Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology (2007) 1.20
Performance of rapid tests for detection of avian influenza A virus types H5N1 and H9N2. J Clin Microbiol (2006) 1.19
Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog (2009) 1.18
Influenza vaccines. Vaccine (2009) 1.17
H5N1 vaccines in humans. Virus Res (2013) 1.16
Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat. Influenza Other Respir Viruses (2007) 1.12
Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS One (2011) 1.10
Detection of H5 avian influenza viruses by antigen-capture enzyme-linked immunosorbent assay using H5-specific monoclonal antibody. Clin Vaccine Immunol (2007) 1.09
Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J Virol (2007) 1.09
Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge. J Virol (2012) 1.04
Influenza virus protecting RNA: an effective prophylactic and therapeutic antiviral. J Virol (2008) 1.02
Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol (2010) 1.01
Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol (2011) 0.99
A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis (2009) 0.97
Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials). Influenza Other Respir Viruses (2008) 0.95
Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol (2011) 0.93
Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir. Antiviral Res (2012) 0.91
An adenovirus vector-mediated reverse genetics system for influenza A virus generation. J Virol (2007) 0.89
Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J Virol (2012) 0.89
Improved antigen yield in pandemic H1N1 (2009) candidate vaccine viruses with chimeric hemagglutinin molecules. J Virol (2011) 0.88
Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respir Viruses (2009) 0.87
Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS One (2012) 0.86
Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine). Influenza Other Respir Viruses (2011) 0.85
Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge. PLoS One (2015) 0.84
Label-free, arrayed sensing of immune response to influenza antigens. Talanta (2010) 0.84
Developing vaccines to combat pandemic influenza. Viruses (2010) 0.84
Structural and antigenic variation among diverse clade 2 H5N1 viruses. PLoS One (2013) 0.83
Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models. Open Microbiol J (2014) 0.82
CHD6, a cellular repressor of influenza virus replication, is degraded in human alveolar epithelial cells and mice lungs during infection. J Virol (2013) 0.80
Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model. Clin Vaccine Immunol (2014) 0.80
An overview of the characteristics of the novel avian influenza A H7N9 virus in humans. Front Microbiol (2015) 0.80
Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected]. PLoS One (2012) 0.79
Specific antibody response of mice after immunization with COS-7 cell derived avian influenza virus (H5N1) recombinant proteins. J Immune Based Ther Vaccines (2007) 0.78
Molecular pathogenesis of H5 highly pathogenic avian influenza: the role of the haemagglutinin cleavage site motif. Rev Med Virol (2015) 0.78
Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Res (2013) 0.77
Protease activation mutants elicit protective immunity against highly pathogenic avian influenza viruses of subtype H7 in chickens and mice. Emerg Microbes Infect (2013) 0.77
Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine. PLoS One (2014) 0.77
Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses. Vaccine (2012) 0.76
An Innovative Pseudotypes-Based Enzyme-Linked Lectin Assay for the Measurement of Functional Anti-Neuraminidase Antibodies. PLoS One (2015) 0.76
Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res (2013) 0.75
Identification of Influenza A/PR/8/34 Donor Viruses Imparting High Hemagglutinin Yields to Candidate Vaccine Viruses in Eggs. PLoS One (2015) 0.75
A step closer to meeting the threat of avian influenza. PLoS Med (2006) 0.75
Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. Vaccine (2015) 0.75
Efficient generation of recombinant influenza A viruses employing a new approach to overcome the genetic instability of HA segments. PLoS One (2015) 0.75
Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med (2009) 42.75
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med (2003) 29.55
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A (2002) 20.48
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med (2009) 9.06
Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. J Virol (2005) 7.36
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res (2005) 6.32
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis (2002) 5.92
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis (2007) 5.21
Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med (2006) 5.14
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother (2008) 5.04
Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature (2009) 4.49
Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29
RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell (2010) 3.59
H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science (2013) 3.33
Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol (2002) 3.04
The NS1 gene contributes to the virulence of H5N1 avian influenza viruses. J Virol (2006) 3.03
Characterization of highly pathogenic H5N1 avian influenza A viruses isolated from South Korea. J Virol (2005) 2.97
A single-amino-acid substitution in the NS1 protein changes the pathogenicity of H5N1 avian influenza viruses in mice. J Virol (2007) 2.80
Evolution of H9N2 influenza viruses from domestic poultry in Mainland China. Virology (2005) 2.72
Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host. PLoS Pathog (2009) 2.62
Continued evolution of H5N1 influenza viruses in wild birds, domestic poultry, and humans in China from 2004 to 2009. J Virol (2010) 2.62
Genetic epidemiology of diabetes. J Clin Invest (2005) 2.53
Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol (2005) 2.51
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol (2006) 2.47
The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A (2002) 2.39
Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis (2013) 2.38
Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J (2010) 2.29
Pause on avian flu transmission research. Science (2012) 2.24
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A (2006) 2.23
Association of the influenza A virus RNA-dependent RNA polymerase with cellular RNA polymerase II. J Virol (2005) 2.19
NS2/NEP protein regulates transcription and replication of the influenza virus RNA genome. J Gen Virol (2009) 2.16
Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding. J Biol Chem (2003) 2.15
Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Virology (2005) 2.10
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (2006) 2.10
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A (2009) 2.08
Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol (2006) 2.08
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis (2007) 2.02
H5N1 hybrid viruses bearing 2009/H1N1 virus genes transmit in guinea pigs by respiratory droplet. Science (2013) 1.97
Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis (2006) 1.96
Role of ran binding protein 5 in nuclear import and assembly of the influenza virus RNA polymerase complex. J Virol (2006) 1.93
Evolution of highly pathogenic H5N1 avian influenza viruses in Vietnam between 2001 and 2007. PLoS One (2008) 1.91
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Innate immunity in aging: impact on macrophage function. Aging Cell (2004) 1.88
Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog (2011) 1.87
Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007-2008. PLoS One (2009) 1.85
Essential role of sequestosome 1/p62 in regulating accumulation of Lys63-ubiquitinated proteins. J Biol Chem (2008) 1.83
Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther (2011) 1.81
A naturally occurring deletion in its NS gene contributes to the attenuation of an H5N1 swine influenza virus in chickens. J Virol (2007) 1.80
The first confirmed human case of avian influenza A (H5N1) in Mainland China. Lancet (2006) 1.79
Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Res (2007) 1.77
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
In vitro assembly of PB2 with a PB1-PA dimer supports a new model of assembly of influenza A virus polymerase subunits into a functional trimeric complex. J Virol (2005) 1.73
H5N1 influenza viruses: outbreaks and biological properties. Cell Res (2009) 1.72
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res (2009) 1.66
Functional association between viral and cellular transcription during influenza virus infection. Rev Med Virol (2006) 1.65
Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun (2011) 1.65
H6 influenza viruses pose a potential threat to human health. J Virol (2014) 1.64
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother (2010) 1.63
Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol (2011) 1.62
Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine (2003) 1.61
Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology (2002) 1.57
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Two amino acid residues in the matrix protein M1 contribute to the virulence difference of H5N1 avian influenza viruses in mice. Virology (2008) 1.55
Genetic analysis and antigenic characterization of swine origin influenza viruses isolated from humans in the United States, 1990-2010. Virology (2011) 1.55
Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain. PLoS Pathog (2012) 1.55
Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem (2008) 1.51
Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep (2015) 1.48
A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology (2008) 1.48
Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine (2003) 1.48
The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine (2011) 1.44
Low pathogenic avian influenza A (H7N2) virus infection in immunocompromised adult, New York, USA, 2003. Emerg Infect Dis (2012) 1.43
Targeting Importin-α7 as a Therapeutic Approach against Pandemic Influenza Viruses. J Virol (2015) 1.41
Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology (2008) 1.41
The PA protein directly contributes to the virulence of H5N1 avian influenza viruses in domestic ducks. J Virol (2010) 1.40
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother (2013) 1.39
Key molecular factors in hemagglutinin and PB2 contribute to efficient transmission of the 2009 H1N1 pandemic influenza virus. J Virol (2012) 1.37
Seasonal and pandemic influenza surveillance considerations for constructing multicomponent systems. Influenza Other Respir Viruses (2009) 1.35
Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res (2004) 1.35